KANSAS CITY, Mo. – St. Luke’s Mid-America Heart Institute today announced results from the STEP HFpEF DM trial, showing that semaglutide 2.4 mg once weekly significantly reduced heart failure-related symptoms and physical symptoms compared to placebo. significantly reduced physical limitations, improved motor function, and resulted in greater weight loss in adults with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes.

The results of this study were presented today at the American College of Cardiology’s Scientific Sessions in Atlanta, Georgia, and simultaneously published in a journal. New England Medical Journaldemonstrated significant improvement in the patient-reported Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), which measures symptoms and physical limitations due to heart failure.

Obesity and type 2 diabetes are common in heart failure patients with preserved ejection fraction and are characterized by severe symptoms and functional impairment. Currently, there are no approved treatments that specifically target obesity-related heart failure with preserved ejection fraction in patients with type 2 diabetes.

“Obesity forms a ‘common ground’ that can lead to the development of heart failure with preserved ejection fraction and type 2 diabetes, and patients with both diseases suffer a particularly high symptom burden. However, there are few treatment options available,” he said. Mikhail Kosiborod is a principal investigator and cardiologist at St. Luke’s Mid-America Heart Institute in Kansas City, USA. “Today’s results, especially when combined with those from the STEP-HFpEF trial, open a new chapter in targeting obesity as a new and effective treatment strategy in patients with obesity-associated HFpEF, with or without diabetes.”

The mean change in KCCQ-CSS was an increase of 13.7 points with semaglutide 2.4 mg versus 6.4 points with placebo over 52 weeks, resulting in an estimated treatment difference of 7.3 points (p<0.001). The mean change in body weight was a 9.8% decrease with semaglutide 2.4 mg versus a 3.4% decrease for him with placebo, resulting in an estimated treatment difference of 6.4% for him (p<0.001).

STEP HFpEF DM also showed an average increase in 6-minute walking distance (6MWD) of 12.7 meters over 52 weeks with semaglutide versus an average decrease of 1.6 meters with placebo, for an estimated treatment difference of 14.3 meters (p=0.008) has been proven. Semaglutide also reduced inflammation, as measured by high-sensitivity C-reactive protein (hsCRP) levels.

The safety profile of semaglutide 2.4 mg was consistent with previous studies. No serious adverse events were observed with semaglutide 2.4 mg compared to placebo.

About heart failure with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes
64 million people worldwide have heart failure. HFpEF is currently the most common form of heart failure, accounting for approximately 50% of all cases. Importantly, 80% of patients with HFpEF are overweight or obese, and almost half have type 2 diabetes.

About the STEP HFpEF program
The primary objective of the STEP HFpEF Diabetes Study was to investigate the effects of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo on symptoms, physical function, and body weight in patients with obesity-related HFpEF and type 2 diabetes. did. STEP HFpEF enrolled 616 people with symptomatic HFpEF (ejection fraction ≥45%) and obesity (BMI ≥30 kg/m2). The dual primary endpoints were change in her KCCQ-CSS from baseline to week 52 and change in weight from baseline to week 52. Key secondary endpoints were change in 6MWD from baseline to week 52, stratified composite endpoint (all-cause death, heart failure events, difference in KCCQ-CSS change, 6MWD from baseline to week 52) difference in change), and C reactivity change. Protein from baseline (screening) to week 52.

The previously published STEP HFpEF trial (a separate study of 529 participants with obesity-related HFpEF who did not have type 2 diabetes) also demonstrated significant reductions in heart failure-related symptoms and physical limitations, as well as significant improvements in motor function. The degree of improvement and weight loss was demonstrated. Comparison of semaglutide and placebo.

About St. Luke’s Mid-America Heart Institute
Saint Luke’s Mid America Heart Institute is part of Saint Luke’s Health System, a teaching affiliate of the University of Missouri-Kansas City School of Medicine, and one of the nation’s premier cardiovascular programs. Its legacy of innovation began more than 40 years ago when it opened as the nation’s first freestanding heart hospital. Since then, the Heart Institute has specialized in cardiology, cardiovascular surgery, diagnostic imaging, heart failure, transplantation, heart disease prevention, cardiometabolic disease, women’s heart disease, electrophysiology, outcomes research, and health economics. St. Luke’s Mid-America Heart Institute cardiologists provide personalized cardio-oncology care, where experts diagnose heart disease in patients with a history of or undergoing treatment for cancer, I will treat you.

With more than 100 full-time, board-certified cardiovascular specialists, St. Luke’s Mid-America Heart Institute offers one of the largest heart failure and heart transplant programs in the country and is the leader in the Midwest for transcatheter aortic valve replacement. has the greatest experience in A global educational site on the latest approaches in coronary revascularization. The Heart Institute’s cardiovascular research program includes clinical areas as well as centers of excellence and core laboratories. The center continues to serve as one of his four analysis centers for the American College of Cardiology’s National Cardiovascular Data Registry, along with Duke University, Harvard University, and Yale University.

Saint Luke’s Mid America Heart Institute is ranked 47th in the nation for cardiology, heart and vascular surgery. US News & World Report It is the third hospital in the United States to earn Comprehensive Heart Center designation from the Integrative Commission.